Biliary stent placement combined with 125I seed-strip implantation for malignant obstructive jaundice:analysis of prognostic factors
10.3969/j.issn.1008-794X.2024.07.011
- VernacularTitle:胆道支架联合125I粒子条植入治疗恶性梗阻性黄疸预后因素分析
- Author:
Zeyu YU
1
;
Hui YU
;
Lingfeng DIAO
;
Ran YOU
;
Bin LENG
;
Qingyu XU
;
Guowen YIN
Author Information
1. 210009 江苏南京 江苏省肿瘤医院(南京医科大学附属肿瘤医院)介入放射科,江苏省肿瘤研究所
- Keywords:
malignant obstructive jaundice;
cholangiocarcinoma;
biliary stent;
125I seed;
prognosis
- From:
Journal of Interventional Radiology
2024;33(7):758-762
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the factors affecting the prognosis of patients with malignant obstructive jaundice(MOJ)after receiving biliary stent placement combined with intraluminal brachytherapy with 125I seed-strip implantation.Methods The clinical data of 52 patients with MOJ,who received biliary stent placement combined with intraluminal brachytherapy with 125I seed-strip implantation at the Jiangsu Provincial Cancer Hospital of China between January 2019 and January 2023,were retrospectively analyzed.The difference value between preoperative and postoperative number of lymphoid immune cells was recorded as△X.X-tile software was used to calculate the optimal cut-off value of △X,based on which the patients were divided into two groups.Univariate and multivariate analysis were used to determine the risk factors for overall survival(OS).Results The mean survival time of the 52 patients was(201.0±32.1)days.Univariate analysis indicated that postoperative TACE,preoperative ALT,preoperative AST,△lymphocyte cell,△CD3+T cell,△CD8+T cell,△natural killer cell(NK)and △regulatory cell(Treg)were significantly associated with OS,the differences were statistically significant(all P＜0.05).Multivariate analysis revealed that △lymphocyte cell(P=0.007)and △Treg(P=0.038)were the independent risk factors for OS.Conclusion For MOJ patients whose△lymphocyte is ≥0.237 or △Treg is ≥0.21,a longer OS can be expected after receiving the treatment of biliary stent placement combined with intraluminal brachytherapy with 125I seed-strip implantation.
